ACE inhibitors

Type 2 diabetes can be prevented with early pharmacological intervention

Top

DeFronzo RA, Abdul-Ghani M. Type 2 diabetes can be prevented with early pharmacological intervention. Diabetes Care. 2011;34 Suppl 2:S202-9. In the U.S., ∼ 21 × 10(6) individuals have type 2 diabetes, and twice as many have impaired glucose tolerance (IGT). Approximately 40-50% of individuals with IGT will progress to type 2 diabetes over their lifetime. Therefore, treatment of high-risk individuals with IGT to prevent type 2 diabetes has important medical, economic, social, and human implications.

An assessment of the effect of thiazolidinedione exposure on the risk of myocardial infarction in type 2 diabetic patients

Top

Koro CE, Fu Q, Stender M. An assessment of the effect of thiazolidinedione exposure on the risk of myocardial infarction in type 2 diabetic patients. Pharmacoepidemiol Drug Saf. 2008;17(10):989-986. PURPOSE: To determine the likelihood of myocardial infarction (MI) in type 2 diabetic patients exposed to rosiglitazone and pioglitazone, separately, compared to other antidiabetic therapies.

Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose

Top

DREAM Trial Investigators, Dagenais GR, Gerstein HC, Holman R, et al. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: result of the (DREAM) trial. Diabetes Care. 2008;31(5):1007-14. Epub 2008 Feb 11. Impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG) are risk factors for diabetes, cardiovascular disease (CVD), and kidney disease.

Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease

Top

Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Arch Intern Med. 2008;148(1):30-48.

A managed care organization's use of integrated health management to improve secondary prevention of coronary artery disease

Top

Berthiaume JT, Davis J, Taira DA, Thein KK. A managed care organization's use of integrated health management to improve secondary prevention of coronary artery disease. Am J Manag Care. 2007;13(3):142-7. OBJECTIVE: To evaluate the effect of a managed care organization's multifactorial intervention program in optimizing secondary prevention of coronary artery disease (CAD).

Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes

Top

Ruggenenti P, Perna A, Ganeva M, Ene-Iordache B, Remuzzi G, for the BENEDICT Study Group. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. J Am Soc Nephrol. 2006;17:3472-3481. For assessment of the independent renoprotective effect of blood pressure (BP) control and angiotensin-converting enzyme inhibitor therapy, the relationships of baseline BP, BP reduction, and follow-up BP with the incidence of persistent microalbuminuria were evaluated in 1204 hypertensive patients who had type 2 diabetes and normoalbuminuria and were included in the BErgamo Nephrologic Diabetic Complications Trial (BENEDICT) study. 

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose

Top

Gerstein HC, Yusuf S, Bosch J, et al, for the DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368:1096-1105. Rosiglitazone is a thiazolidinedione that reduces insulin resistance and might preserve insulin secretion.

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

Top

Gerstein HC, Yusuf S, Bosch J, et al, for the DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368:1096-1105. Rosiglitazone is a thiazolidinedione that reduces insulin resistance and might preserve insulin secretion.

Effects of blood pressure lowering and metabolic control on systolic left ventricular function in Type II diabetes mellitus

Top

Andersen NH, Poulsen SH, Poulsen PL, et al. Effects of blood pressure lowering and metabolic control on systolic left ventricular function in Type II diabetes mellitus. Clin Sci (Lond). 2006;111:53-59. Decreased left ventricular long-axis function may be the earliest stage in subclinical heart failure in Type II diabetes.

Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes

Top

Winkelmayer WC, Fischer MA, Schneeweiss S, Wang PS, Levin R, Avorn J. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes. Am J Kidney Dis. 2005;46:1080-1087. National guidelines recommend angiotensin-converting enzyme (ACE)-inhibitor or angiotensin receptor blocker (ARB) therapy in patients with diabetes who also have hypertension and/or proteinuria to retard the progression of renal damage. However, little is known about the adequacy of adherence to these guidelines in elderly patients with diabetes and predictors of such appropriate ACE-inhibitor or ARB use.

1 2 3 Next